B-C Archives | Report Store | Pharma intelligence

show blocks helper

Sort by Price
- Default Order
- Name
- Price
- Date
- Popularity

Click to order products ascending

Display 15 Products per page

Beraprost 314d

$10,000.00

Beraprost (United Therapeutics/Astellas/Kaken Pharmaceutical Co) is an oral chemically stable prostacyclin analog targeting the prostaglandin I2 (PGI2) receptor…
June 19, 2015
Select options
Betrixaban

$10,000.00

Betrixaban (Portola Pharmaceuticals) is an oral, once-daily inhibitor of factor Xa that catalyzes conversion of prothrombin to thrombin, preventing thrombosis. Betrixaban is currently in Phase III development…
August 2, 2016
Select options
Briviacti

$10,000.00

Briviact (brivaracetam; UCB) is a follow-on product to Keppra (levetiracetam; UCB/Otsuka), acting as an anticonvulsant by binding to the synaptic vesicle glycoprotein 2A (SV2A), directly causing…
June 7, 2016
Select options
Complera

$10,000.00

Complera (rilpivirine/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Johnson & Johnson) is a single-tablet regimen for the treatment of HIV-1 infection.
December 11, 2015
Select options
Cubicin

$10,000.00

Cubicin is a cyclic lipopeptide antibacterial that has a unique mechanism of action. It causes rapid depolarization of the bacterial cell membrane potential upon binding to the membrane.
September 10, 2014
Select options
Buparlisibi

$10,000.00

Buparlisib is a pan-PI3K inhibitor that attempts to counteract the dysregulation of the PI3K/protein kinase B (AKT) pathway in cancerous tissues…
May 2, 2016
Select options
blisibimod

$10,000.00

Blisibimod is a selective antagonist of B-cell activating factor (BAFF)/B lymphocyte stimulator (BLyS) that is in Phase III development for SLE. Elevated levels of BAFF have also been associated with several B-cell-mediated autoimmune diseases including…
April 5, 2016
Select options
Bax 817

$10,000.00

BAX 817 is an rfVIIa therapy in development by Baxalta for patients with hemophilia A or B with inhibitors. FVIIa therapy can circumvent the need for fVIII and fIX in the coagulation cascade by directly activating factor X…
March 14, 2016
Select options
Bococizumab

$10,000.00

Bococizumab is an antidyslipidemic humanized antibody that inhibits PCSK9. PCSK9 is a protease involved in the intracellular and extracellular regulation of LDL receptor (LDLR) expression…
June 29, 2016
Select options
Belviq

$10,000.00

Belviq (lorcaserin; Eisai) is a selective agonist of 5-HT2C serotonin receptors. These receptors are concentrated in the hypothalamus of the brain and are believed to play an important role in regulating food intake.
September 9, 2016
Select options
Brilinta

$10,000.00

Brilinta (ticagrelor; AstraZeneca/The Medicines Company) is an antiplatelet agent designed to inhibit blood clot formation. It works by reversibly binding to the blood platelets’ adenosine diphosphate (ADP) P2Y12 receptor…
April 14, 2016
Select options
Baraclude

$10,000.00

Baraclude (entecavir; Bristol-Myers Squibb) is a recommended first-line treatment option in US, EU, and Asian guidelines, and was the top-selling hepatitis B therapy in 2014.
May 14, 2015
Select options
Brintellix

$10,000.00

Brintellix (vortioxetine; Lundbeck/Takeda) is the latest antidepressant to be approved in the US for major depressive disorder. The drug follows a successful line of antidepressants developed by Lundbeck, which includes Cipralex (escitalopram) and Cipramil (citalopram).
May 5, 2016
Select options
Crenezumab

$10,000.00

Crenezumab, created by AC Immune’s SupraAntigen technology platform, is a fully humanized

immunoglobulin G4 monoclonal antibody (MAb) that recognizes amyloid-beta’s mid-section

(Alzforum, 2015).
June 21, 2017
Select options
BMS-986231

$10,000.00

BMS-986231 (Bristol-Myers Squibb/Ligand) is a second-generation prodrug that chemically breaks down to produce nitroxyl (HNO) and an inactive byproduct.
February 15, 2018
Select options

B-C

B-C

Beraprost 314d

Betrixaban

Briviacti

Complera

Cubicin

Buparlisibi

blisibimod

Bax 817

Bococizumab

Belviq

Brilinta

Baraclude

Brintellix

Crenezumab

BMS-986231